$8.140
-0.711 (-8.74%)At close
SOPH News
SOPH Events
Company Expects Adjusted EBITDA Loss Between $29M and $32M
Consensus $93.38M. The company also expects an adjusted EBITDA loss between $29M and $32M.
Company Reports Q2 Revenue of $23.3M, Beating Expectations
Reports Q2 revenue $23.3M, consensus $21.72M. Performance was driven by 60% volume growth in the U.S. and 80% revenue growth in Liquid Biopsy. We delivered an outstanding second quarter, growing revenue 27% year-over-year, while also improving adjusted EBITDA loss by 27%," said CEO Ross Muken.
Sophia Genetics $40M Spot Secondary Re-offered at $4.75
Sophia Genetics $40M Spot Secondary re-offered at $4.75
Sophia Genetics Launches Underwritten Public Offering of Ordinary Shares
Sophia Genetics announced the commencement of a proposed underwritten public offering of its ordinary shares. TD Cowen is acting as the lead book-running manager for the offering.
Sophia Genetics Signs MOU with MSK for Joint Venture
Sophia Genetics has signed a Memorandum of Understanding, or MOU, with Memorial Sloan Kettering Cancer Center, or MSK, relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK in clinical diagnostics and Sophia Genetics' Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world. Sophia DDM, Sophia Genetics' precision medicine platform, has been used to analyze more than 2.5 million cases since 2014. MSK's in-house NGS program has sequenced more than 150,000 tumor samples since 2014, creating a genomic dataset linked to clinical outcomes, pathology, and radiology records. For patients, the proposed precision medicine hub will act as an incubation studio for discoveries, equipped with a deployment platform to deliver new capabilities to patients worldwide. For biopharma partners, the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。